Read by QxMD icon Read

urinary markers bladder cancer

Ahmed I Nossier, Ola S Mohammed, Rasha R Fakhr El-Deen, Ashraf S Zaghloul, Sanaa Eissa
Matrix metalloproteinases (MMPs), in particularly gelatinases (MMP-2 and MMP-9) were reported as urinary markers of bladder cancer. In this work, we developed a simple colorimetric gold nanoparticle (AuNP) assay for rapid and sensitive detection of urinary total gelatinase activity based on the surface plasmon resonance (SPR) property of AuNPs. Gelatin-modified AuNPs were stably suspended in solution even upon addition of an aggregation inducer as 6-mercaptohexan-1-ol (6-MCH). Gelatinases digest gelatin capping...
December 1, 2016: Talanta
Min Hyun Cho, Sung Han Kim, Weon Seo Park, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Kang Hyun Lee
BACKGROUND: Sarcomatoid urothelial carcinoma (SUC) is a rare malignant neoplasm of the urinary bladder comprising 0.2-0.6 % of all histological bladder tumor subtypes. It presents as a high-stage malignancy and exhibits aggressive biological behavior, regardless of the treatment employed. It is defined as histologically indistinguishable from sarcoma and as a high-grade biphasic neoplasm with malignant epithelial and mesenchymal components. The mean age of patients presenting with SUC is 66 years, and the male-to-female ratio is 3:1...
October 20, 2016: World Journal of Surgical Oncology
Zoraida Andreu, Renan Otta Oshiro, Alberto Redruello, Soraya López-Martín, Cristina Gutiérrez-Vázquez, Esperanza Morato, Ana Isabel Marina, Carlos Olivier Gómez, María Yáñez-Mó
Bladder cancer is the second most frequent malignancy of the urinary tract after prostate cancer. Current diagnostic techniques, such as cystoscopy and biopsies are highly invasive and accompanied of undesirable side effects. Moreover, there are no suitable biomarkers for relapse or progression prognosis. We analysed whether the specific composition of microRNAs (miRNAs) and proteins of extracellular vesicles (EVs) that urothelial tumor cells of bladder mucosa release into the urine, could reflect their pathologic condition...
October 14, 2016: European Journal of Pharmaceutical Sciences
Marine De Paoli, Selma Gogalic, Ursula Sauer, Claudia Preininger, Hardev Pandha, Guy Simpson, Andras Horvath, Christophe Marquette
Purpose. Nonmuscle invasive bladder cancer (BCa) has a high recurrence rate requiring lifelong surveillance. Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of recurrent bladder cancer. However, no single marker can achieve the required accuracy. The purpose of this study was to select a multiparameter panel, comprising urinary biomarkers and clinical parameters, for BCa recurrence diagnosis. Experimental Design. Candidate biomarkers were measured in urine samples of BCa patients with recurrence and BCa patients without recurrence...
2016: Disease Markers
Rossana Critelli, Francesca Fasanelli, Marco Oderda, Silvia Polidoro, Manuela Bianca Assumma, Clara Viberti, Mirko Preto, Paolo Gontero, Giuseppina Cucchiarale, Irene Lurkin, Ellen C Zwarthoff, Paolo Vineis, Carlotta Sacerdote, Giuseppe Matullo, Alessio Naccarati
Most bladder cancer (BC) patients need life-long, invasive and expensive monitoring and treatment, making it a serious burden on the health system. Thus, there is a pressing need for an accurate test to assist diagnosis and surveillance of BC as an alternative to cystoscopy. Mutations in human TERT, FGFR3, PIK3CA, and RAS genes have been proposed as potential molecular markers in bladder tumor. Their concomitant presence in urine samples has not been fully explored.We investigated a panel of mutations in DNA from exfoliated urinary cells of 255 BC patients at diagnosis...
September 7, 2016: Oncotarget
Rinni Singh, Jamal A Ansari, Niharika Maurya, Anil Mandhani, Vinita Agrawal, Minal Garg
INTRODUCTION: Epithelial-to-mesenchymal transition (EMT) is a dynamic process in the pathogenesis of urinary bladder cancer. Despite significant advancements in its diagnosis and treatment, the outcomes have more or less remained the same. In the present study, the expression of EMT markers was investigated to evaluate its prognostic significance in patients with non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: The present study was undertaken to examine the expression of EMT markers, including E-cadherin, N-cadherin, vimentin, Snail, Twist, Zeb, and Slug, on 28 bladder tumor tissues (15 cases of NMIBC and 13 of MIBC) using reverse transcription-polymerase chain reaction...
August 9, 2016: Clinical Genitourinary Cancer
Eduardo Ferreira Pedroso de Almeida, Tomás Elias Abdalla, Tiago Pedromonico Arrym, Pamela de Oliveira Delgado, Marcelo Langer Wroclawski, Beatriz da Costa Aguiar Alves, Flávia de S Gehrke, Ligia Ajaime Azzalis, Sarah Alves, Marcos Tobias-Machado, Antonio Carlos de Lima Pompeo, Fernando Luiz Affonso Fonseca
a) Objective: An increase in cell-free DNA was observed in the plasma of many cancer patients. This major biomarker can be used to differentiate patients with malignant neoplasms from those with benign neoplasms or healthy patients. Depending on the characteristic of the tumor, there are qualitative variations in the circulating cell-free DNA. Today, studies on the concentration of fragments of circulating cell-free DNA and their respective sizes in patients with bladder cancer are not plentiful in the literature...
September 4, 2016: Clinical Biochemistry
M Traczyk-Borszynska, E Borkowska, Z Jablonowski, A Jedrzejczyk, M Pietrusinski, B Kaluzewski, M Sosnowski, M Borowiec
The aim of the study was to assess the genetic diversity of bladder cancer and determine the suitability of a proposed molecular marker panel to monitor the course of bladder cancer patients. The study involved 185 patients with diagnosed bladder cancer. The genetic diversity of the bladder cancer was evaluated by the prevalence of mutations in the TP53, HRAS, FGFR3 and WWOX genes. Mutations were detected in 62.2% of the tumor samples. The most frequently mutated genes were FGFR3 (49.7%) and TP53 (16.2%). No mutation was observed in the WWOX gene...
September 6, 2016: Neoplasma
Jean-Pierre Roperch, Bernard Grandchamp, François Desgrandchamps, Pierre Mongiat-Artus, Vincent Ravery, Idir Ouzaid, Morgan Roupret, Véronique Phe, Calin Ciofu, Florence Tubach, Olivier Cussenot, Roberto Incitti
BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is a high incidence form of bladder cancer (BCa), where genetic and epigenetic alterations occur frequently. We assessed the performance of associating a FGFR3 mutation assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of NMIBC patients. METHODS: We used allele specific PCR to determine the FGFR3 mutation status for R248C, S249C, G372C, and Y375C. We preselected 18 candidate genes reported in the literature as being hypermethylated in cancer and measured their methylation levels by quantitative multiplex-methylation specific PCR...
2016: BMC Cancer
Xiang Zhuang, Mengxin Lv, Zhenyu Zhong, Luyu Zhang, Rong Jiang, Junxia Chen
BACKGROUND: Integrin-linked kinase (ILK) is a multifunctional adaptor protein which is involved with protein signalling within cells to modulate malignant (cancer) cell movement, cell cycle, metastasis and epithelial-mesenchymal transition (EMT). Our previous experiment demonstrated that ILK siRNA inhibited the growth and induced apoptosis of bladder cancer cells as well as increased the expression of Ribonuclease inhibitor (RI), an important cytoplasmic protein with many functions. We also reported that RI overexpression inhibited ILK and phosphorylation of AKT and GSK3β...
2016: Journal of Experimental & Clinical Cancer Research: CR
Won Tae Kim, Pildu Jeong, Chunri Yan, Ye Hwan Kim, Il-Seok Lee, Ho-Won Kang, Yong-June Kim, Sang-Cheol Lee, Sang Jin Kim, Yong Tae Kim, Sung-Kwon Moon, Yung-Hyun Choi, Isaac Yi Kim, Seok Joong Yun, Wun-Jae Kim
BACKGROUND: There is growing interest in circulating nucleic acids as cancer detection biomarkers. Therefore, the aim of the present study was to identify a key urinary cell-free RNA marker that may assist in the diagnosis of BC. RESULTS: Five cell-free RNAs were selected as candidate cell-free RNAs from tissue microarray data. An area under the curve (AUC) cut-off value of 0.7 in receiver operating characteristic (ROC) curve analysis identified four urinary cell-free RNAs for further analysis (CDC20, ESM1, UBE2C, and CA9; AUC = 0...
August 12, 2016: Oncotarget
Sarah L Kerns, Leila Dorling, Laura Fachal, Søren Bentzen, Paul D P Pharoah, Daniel R Barnes, Antonio Gómez-Caamaño, Ana M Carballo, David P Dearnaley, Paula Peleteiro, Sarah L Gulliford, Emma Hall, Kyriaki Michailidou, Ángel Carracedo, Michael Sia, Richard Stock, Nelson N Stone, Matthew R Sydes, Jonathan P Tyrer, Shahana Ahmed, Matthew Parliament, Harry Ostrer, Barry S Rosenstein, Ana Vega, Neil G Burnet, Alison M Dunning, Gillian C Barnett, Catharine M L West
Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. Development of a test predicting risk of toxicity could benefit many cancer patients. We aimed to meta-analyze individual level data from four genome-wide association studies from prostate cancer radiotherapy cohorts including 1564 men to identify genetic markers of toxicity. Prospectively assessed two-year toxicity endpoints (urinary frequency, decreased urine stream, rectal bleeding, overall toxicity) and single nucleotide polymorphism (SNP) associations were tested using multivariable regression, adjusting for clinical and patient-related risk factors...
August 2016: EBioMedicine
Jamie J D'Costa, James C Goldsmith, Jayne S Wilson, Richard T Bryan, Douglas G Ward
For over 80 years, cystoscopy has remained the gold-standard for detecting tumours of the urinary bladder. Since bladder tumours have a tendency to recur and progress, many patients are subjected to repeated cystoscopies during long-term surveillance, with the procedure being both unpleasant for the patient and expensive for healthcare providers. The identification and validation of bladder tumour specific molecular markers in urine could enable tumour detection and reduce reliance on cystoscopy, and numerous classes of biomarkers have been studied...
2016: Bladder Cancer
S Pospisilova, E Pazourkova, A Horinek, A Brisuda, I Svobodova, V Soukup, J Hrbacek, O Capoun, T Hanus, J Mares, M Korabecna, M Babjuk
Urinary bladder carcinoma contributes to 4% of newly diagnosed oncological diseases in the Czech Republic. Biomarkers for its early non-invasive detection are therefore highly desirable. Urine seems to be an ideal source of such biomarkers due to the content of cell-free nucleic acids, especially microRNAs (miRNAs).To find potential biomarkers among miRNAs in urine supernatant, we examined in total 109 individuals (36 controls and 73 bladder cancer patients) in three phases. In the first - discovery - phase, microarray cards with 381 miRNAs were used for miRNA analysis of 13 controls and 46 bladder cancer patients...
2016: Neoplasma
D S Mikhailenko, N E Kushlinskii
All around the world, more than 330 thousands cases of bladder cancer are registered annually hence representing actual problem of modern oncology. Still in demand are search and characteristic of new molecular markers of bladder cancer detecting in tumor cells from urinary sediment and having high diagnostic accuracy. The studies of last decade, especially using methods of genome-wide sequencing, permitted to receive a large amount of experimental data concerning development and progression of bladder cancer The review presents systematic analysis of publications available in PubMed data base mainly of last five years...
February 2016: Klinicheskaia Laboratornaia Diagnostika
Lin-Feng Zheng, Wen-Yong Sun
Bladder cancer is the most common cancer of the urinary tract. A quarter of bladder cancer patients presenting with muscle-invasive bladder cancer (MIBC) suffer significant morbidity and succumb to the disease. MicroRNA (miRNA) from tissue, urine or blood samples of MIBC patients have been demonstrated to differ from healthy individuals, and possibly have diagnostic value. The aim of the present meta-analysis was to access the overall diagnostic accuracy comprehensively and quantitatively. Systematic searching in PubMed, Web of Science, Embase and Chinese National Knowledge Infrastructure database was conducted...
August 2016: Biomedical Reports
Kun-Hung Shen, Chien-Feng Li, Lan-Hsiang Chien, Cheng-Hao Huang, Chia-Cheng Su, Alex C Liao, Ting-Feng Wu
Human galectin-1 is a member of galectin family, proteins with conserved carbohydrate-recognition domains that bind galactoside. Galectin-1 is highly expressed in various tumors and participates in various oncogenic processes. However, detailed description of the function of galectin-1 in urinary bladder urothelial carcinoma has not been provided nowadays. Our previous cohort investigation demonstrated that galectin-1 is associated with tumor invasiveness and a possible independent prognostic marker of urinary bladder urothelial carcinoma...
July 21, 2016: Cancer Science
Wassim Kassouf, Samer L Traboulsi, Bernd Schmitz-Dräger, Joan Palou, Johannes Alfred Witjes, Bas W G van Rhijn, Herbert Barton Grossman, Lambertus A Kiemeney, Peter J Goebell, Ashish M Kamat
OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) comprises a wide spectrum of tumors with different behaviors and prognoses. It follows that the surveillance for these tumors should be adapted according to the risks of recurrence and progression and should be dynamic in design. METHODS AND MATERIALS: Medline search was conducted from 1980 to 2016 using a combination of MeSH and keyword terms. The highest available evidence was reviewed to define different risk groups in NMIBC...
October 2016: Urologic Oncology
Yong-June Kim, Wun-Jae Kim
Urothelial carcinomas of the urinary bladder have diverse biological and functional characteristics, and numerous factors are likely to be involved in recurrence, progression, and patient survival. While several molecular markers used to evaluate the development and prognosis of bladder cancer have been studied, they are of limited value; therefore, new molecular parameters useful for predicting the prognosis of bladder cancer patients (particularly patients at high risk of progression and recurrence) are required...
June 2016: Investigative and Clinical Urology
Kiyoshi Higashi, Nobuaki Fujii, Masahiko Kushida, Keita Yamada, Noriyuki Suzuki, Koichi Saito, Taro Tachibana
Pancreatic ductal adenocarcinoma is an aggressive tumor with a poor prognosis. Biomarkers that can detect the tumor in its early stages when it may be amenable to curative resection might improve prognosis. To discover novel markers expressed in primary pancreatic cancer, we generated a panel of monoclonal antibodies against pancreatic ductal adenocarcinoma cell line BxPC3 using a rat medial iliac lymph node method. The antigen recognized by 1B5A5 was expressed on the cell surface and secreted into the conditioned medium of BxPC3 cells, and characterized as glycoproteins with molecular mass between 60 and 90 kDa...
June 2016: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"